Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma – first line
NIHR HSRIC
Record ID 32016001029
English
Authors' recommendations:
Nivolumab and ipilimumab are two drugs used to treat renal cell carcinoma, which is the most common form of kidney cancer. Many people with kidney cancer show no symptoms for many years and are often diagnosed late, after the cancer has spread. Nivolumab and ipilimumab are delivered straight into the blood and work by altering the body's immune reaction to the cancer. Some studies suggest that the combination of these two drugs may offer a new treatment option for patients with advanced renal cell carcinoma or in patients whose disease has spread to other parts of the body.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/nivolumab-opdivo-and-ipilimumab-yervoy-for-advanced-or-metastatic-renal-cell-carcinoma-first-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antibodies, Monoclonal
- Antineoplastic Agents
- Carcinoma, Renal Cell
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.